# MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

> **NCT00543582** · PHASE2 · TERMINATED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 23 (actual)

## Conditions studied

- Hodgkin Lymphoma
- Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

## Interventions

- **DRUG:** MGCD0103 and Azacitidine

## Key facts

- **NCT ID:** NCT00543582
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-10
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All Celgene-sponsored trials with MGCD0103 will be closed.
- **Last updated:** 2015-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00543582

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00543582, "MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00543582. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*